If there is a great new hope in the treatment of cancer, the immune system is it. Innate and adaptive immunity either promote or attenuate tumorigenesis and so can have opposing effects on therapeutic outcome.
ISGF3 IFN-stimulated gene factor 3;
JAK Janus kinase;
LGP2 laboratory of genetics and physiology 2; 
Introduction
The sensing of altered-self, such as changes in tissue/organ homeostasis or integrity, and hence the need to detect and protect against potential danger (e.g., cellular stress, damage, or abnormal death), is upsetting the traditional view of immunity as a response to solely alien microbes and molecules 1 . In particular, it is now clear that cancer cells, either transformed by foreign pathogens (e.g., human papillomavirus, hepatitis-B virus,
Epstein-Barr virus, human T-lymphotropic virus-I, hepatitis-C virus, Kaposi's sarcoma herpesvirus, or
Helicobacter pylori) or totally aseptic, differ antigenically from their normal counterparts and, similar to virus-infected cells, emit danger signals to license the immune system. Such signals, best known as damageassociated molecular patterns (DAMPs), de facto favor the establishment of a productive and long-lasting immune response allowing to clear virus-infected cells (because they express virus-encoded proteins) and tumor cells (because they express tumor-associated antigens, TAA). Intriguingly, anti-viral and anti-tumor immune responses share common DAMPs, among which Type-I-interferons (IFNs) emerge as the primum movens for the sequential events bridging innate and cognate immunity 2 .
IFNs and their receptors are a subset of the class-2 α-helical cytokines that have been found in all vertebrates, although a systemic phylogenetic knowledge is lagging behind. Based on criteria such as their cellular source, their general biologic properties, their gene structure and the receptor through which they signal, IFNs have been categorized into three distinct families: Type-I, Type-II and Type-III. In humans, Type-I-IFNs consist of 13 partially homologous IFN-α cytokines, a single IFN-β and several not yet well characterized single gene products (IFN-ε, IFN-τ, IFN-κ, IFN-ω, IFN-δ and IFN-ζ) all of which are mostly non-glycosylated proteins of 165--200 aminoacids 3 . The reason for the existence of multiple subtypes may be ascribed to differences in tissue-specific expression, the kinetic of production and the spectrum of biological activities 4 . Almost all cells in the body can produce Type-I-IFNs following the recognition of molecules, such as foreign and self nucleic-acids, and a minority of other non-nucleic-acids (collectively known as pathogen associated molecular patterns, PAMPs) by the so-called pathogen recognition receptors (PRRs) located in the plasma membrane, cytosol or endosomal compartments 5 
Pathways triggering production of Type-I-IFNs
As reported in the introduction, Type-I-IFNs can be produced by all nucleated cells in the body. The involved in autoregulation 16 . Although presenting a similar organization, LGP2 lacks the N-terminal CARD and is currently thought to be a regulator of RIG-I and MDA5 rather than a bona fide PRR 17 . Upon binding to double-stranded-RNAs, RLRs directly interact with a downstream molecule named independently by four different groups as mitochondrial antiviral signalling adaptor (MAVS) 18 , IFNβ promoter stimulator (IPS)-1 19 , virus-induced signalling adaptor (VISA) 20 , and CARD adaptor-inducing IFNβ (CARDIF) 21 . As for TLRs, the association with this mitochondrial-resident protein via CARD induces Type-I-IFN production by IKKε/TBK1 complex.
NLRs are cytoplasmic PRRs with a tripartite structure consisting of a variable N-terminal effector domain, a middle nucleotide-binding domain and a C-terminal leucine-rich repeat domain 22 . Among the more than 20
NLRs identified in humans so far 22 , only the cytosolic molecular sensor NOD-containing protein 2 (NOD2)
was clearly shown to recognize single-stranded RNAs leading to Type-I-IFN production through a mechanism dependent on MAVS and IRF3 activation 23 . Other NLRs are mainly described as regulators of the major histocompatibility complex-I (MHC-I) 24 , the inflammasome multiprotein complex assembly 25 and regulated cell death pathways (apoptosis, pyroptosis and pyronecrosis 22 ). All these functions go beyond their sensing of DAMPs and PAMPs, which instead remains largely unknown.
The first described PRR for DNA, and still the only known endosomal-based DNA sensor, was TLR9 26 .
TLR9 is expressed preferentially in plasmacytoid dendritic cells (pDCs) and acts as a potent inducer of IFN-α via a signalling network dependent on MyD88 and IRF7 26 . Moreover, DNA can end-up in the cytosol through several routes (e.g., intracellular pathogens, lysosome-internalized exogenous DNA from dead cells, or endogenous DNA replication debris) where it can be recognized by more than ten cytosolic receptors 27 . The search for cytosolic DNA sensors first led to the identification of the DNA-dependent activator of IRFs (DAI) 28 . When exogenously expressed in L929 murine fibroblasts, DAI increased Type-I-IFN production in a dose-dependent manner following stimulation by both B-and Z-form DNA 28 . Similarly, knockdown of DAI with specific siRNAs impaired Type-I-IFN production in response to cytosolic DNA 28 . RNA polymerase-III (POLR3), the second cytosolic DNA sensor discovered, was reported to use AT-rich and herpesvirus DNA as a template to produce 5′-triphosphate RNAs, which then induce Type-I-IFNs by activating RIG-I 29 . However, POLR3 could not account for DAI-independent sensing of non-AT-rich DNA suggesting the existence of additional cytosolic DNA sensors. Remarkably, an adaptor molecule referred to as stimulator of IFN genes (STING) was identified as being crucial for recognizing cytoplasmic DNA and inducing innate immune responses to a variety of DNA pathogens even including certain RNA viruses 30 . Nonetheless, despite the wealth of recent information on the mechanisms whereby STING contributes to signal Type-I-IFN induction, the upstream DNA-sensing events remain largely unknown. Recent evidence suggests that cytosolic DNA is perceived by the cyclic GMP-AMP synthase (cGAS), which then becomes catalytically active and generates the second messenger cyclic guanosine monophosphate-adenosine monophosphate (cGAMP). cGAMP in turn binds to STING stimulating its transit from the endoplasmic-reticulum to perinuclear endosomes where it triggers IRF3 activation via TBK1 30, 31 . Of note, STING-dependent Type-I-IFN production can also be activated by single-stranded-DNA resulting from DNA damage or replication stress 32 , by mitochondrial DNA released following apoptotic mitochondrial outer membrane permeabilization 33 and possibly by retroelements not properly metabolized by the three prime repair exonuclease (TREX)1 34 .
Two essential mediators of distinct DNA-activated innate responses seem to be the PYHIN proteins absent in melanoma (AIM)2 and IFN-γ-inducible (IFI)16 35, 36 . Moreover, the DDX3, DDX41, DHX9, DDX60, DDX1
and DHX36 helicases were recently involved in DNA immune sensing through a pathway dependent on STING and TBK1 37 . In particular, Liu and co-workers found that, in mouse splenic myeloid DCs with limited basal IFI16 expression, DDX41 was the initial sensor of cytoplasmic DNA inducing Type-I-IFNs and the subsequent IFI16 expression, with this latter operating as an amplifier of innate responses 37 .
Along with PAMPs and DAMPs, Type-I-IFNs can also be produced in response to rare physiological stimuli such as colony stimulating factor (CSF)1 38 , receptor activator of nuclear factor κB (NF-κB) ligand (RANK) 39 and estrogens 40 . More recently, an intriguing correlation between Type-I-IFNs and tumor protein p53 (TP53/p53) was reported 41 . In sum, the absence of p53 was associated with extensive DNA hypomethylation, which resulted in a massive transcription of normally silent retroelements and satellite DNA. The subsequent accumulation of these newly generated double-stranded-RNA species triggered a "suicidal" Type-I-IFN response 41 .
Overall, Type-I-IFN production is tightly regulated by major families of heterologous receptors engaged by diverse ligands during infectious and cancerous diseases. Each of the Type-I-IFN subtypes induces a unique and partially overlapping set of ISGs, able to act at different steps of virus and cancer life cycle.
ISGs: a complex net of host defences
Type-I-IFN-mediated innate immune response is hardwired within genomes to provide a robust first-line of host defence and preserve homeostasis. Once secreted by cells, Type-I-IFNs bind to the same ubiquitous heterodimeric IFNAR1-IFNAR2 receptor 42 . The assembly of IFNAR1, Type-I-IFN and IFNAR2 in a 1:1:1 stoichiometry seems to occur via a two-step process whereby Type-I-IFN first binds to one IFNAR and then promotes the recruitment of the second IFNAR without identified interactions between the two IFNARs 42 .
Once assembled, this ternary complex promotes the phosphorylation and activation of IFNAR1-associated 
Type-I-IFNs in cancer
Type-I-IFNs are back in the oncological spotlight due to a greater understanding of their role in tumor generation, pathogenesis and treatment. Regardless of their source in the tumor microenvironment (TME), Type-I-IFNs have the potential to exert their opposed anti-and pro-tumorigenic actions acting directly on tumor cells and indirectly on immune infiltrating cells (Figure 2) .
Cancer-intrinsic effects of Type-I-IFNs
The cancer cell-intrinsic effectiveness of Type-I-IFNs is well documented in experimental animal systems and is reported to depend on specific cellular effects such as growth inhibition 47 , modulation of apoptosis 48 , differentiation 49 , migration 49 The in vitro modulation of cultured tumor cells by Type-I-IFNs has been documented. Some early reports showed that IFN-β has the ability to boost human leucocyte antigen (HLA)-class-I expression 62 (panel 3, Figure 2 ) and modulate the antigenic landscape of cultured melanoma cells 63 (panel 4, Figure 2 ). More recently, these discoveries were characterized by Dunn et al., who showed that IFN-β simultaneously augments TAA (e.g., Melan-A/MART-1, gp100, and MAGE-A1) and HLA-class-I thus increasing the likelihood of improved immune recognition and cytotoxic killing of tumor targets, respectively 64 .
The EMT is a process by which epithelial cells lose their polarization and cell-cell contacts and undergo remarkable morphologic changes switching from an epithelial cobblestone phenotype to an elongated fibroblastic phenotype 65 . The EMT provides for the evolution of cancer cells to the metastatic phenotype and contributes to their invasiveness, stemness and drug resistance 65 . In a recent study, the IFN-α-inducible protein-27 was associated with the EMT marker vimentin in ovarian cancer 66 (panel 6, Figure 2 ). This phenomenon finally led to chemoresistant cells with a cancer stem cell (CSC) phenotype 66 . CSCs are defined as the reservoir of a chemoresistant niche within the tumor and the driving force for tumor relapse 67, 68 .
Mounting 
Cancer-extrinsic effects of Type-I-IFNs
In addition to the direct impact on cancer cells, Type-I-IFNs have extrinsic effects on tumors regulating processes such as angiogenesis and immunity 77 . Type I IFNs have been long recognized as powerful angiogenesis inhibitors. The effects of Type I IFNs on the vasculature have been mainly attributed to the downregulation of vascular endothelial growth factor (VEGF) expression as well as to the impairment of endothelial cell proliferation and migration 78 (panel 9, Figure 2) . Seminal experimental findings from Schreiber's group strongly suggest that, although the immune system plays a major part in restraining the development of cancer, it may also promote the emergence of tumors that escape immune control 79 .
According to the immune-editing model, malignant cells, initially held in check by immune-surveillance means, can grow into clinically manifest tumors provided that (1) they lose the cancer molecular determinants that make them recognizable by immune-effectors (immune-selection) or (2) they actively counteract immune responses (immune-suppression) 79 . Immuno-editing consists of three phases: first, at an early stage malignant cells are recognized and eradicated by immune-effector cells (elimination); second, at a later stage small tumors are still held in check by increasingly less proficient immune responses (equilibrium); and finally, neoplastic cells lose their antigenic properties or establish potent immune-suppressive networks, thus avoiding any control (escape) 79 . Most noteworthy, Dunn et al proved that Type-I-IFNs intervene in all these three phases 80 . They demonstrated that endogenously produced Type-I-IFNs were required, in immunocompetent mice, to reject highly immunogenic 3'-methylcholanthrene (MCA)-induced sarcomas and to prevent the outgrowth of primary carcinogen-induced tumors. Furthermore, they observed that several MCA-induced sarcomas from Ifnar1 /mice were rejected in a T cell-dependent manner in wild-type mice, which suggests that tumors arising in the absence of Type-I-IFN responsiveness are more immunogenic than tumors growing in IFNAR competent hosts 80 .
The earliest indication that Type-I-IFNs could stimulate extrinsic antitumor effects was reported in a mouse model of lymphocytic leukaemia, in which it was shown that survival rates were increased by administering crude (mixed-type) IFN preparations, irrespective of whether tumor cells themselves were intrinsically sensitive to the anti-proliferative actions of these IFN preparations 81 . From then, an impressive number of instrumental studies in both mice and humans confirmed the plethora of mechanisms by which Type-I-IFNs act on immune cells to mount a strong antitumor response. In the early 1990s, Ferrantini and colleagues showed that highly metastatic Friend leukemia cells genetically modified to secrete IFN-α1 exhibited a marked loss of their tumorigenic potential when injected into syngeneic immunocompetent mice 82 , and inhibited the growth of metastatic parental cells in transplantation assays mainly through CD8 + CTLs 83 .
Despite these encouraging data, the clinical development of Type-I-IFNs remained underappreciated for many years. In the past two decades the findings that IFN-α induced the differentiation/activation of DCs (panel 10, Figure 2 ) in both mice 84 and humans 85 have spurred the ideation of new immunotherapeutic regimens. Today, new attention is given to Type-I-IFNs as crucial factors bridging innate and adaptive immunity. Several studies support the importance of Type-I-IFNs as a stimulus for the production of various cytokines (e.g., TNF, IL-1, IL-6, IL-8, IL-12, and IL-18) by macrophages 86 (panel 11, Figure 2) , and as factors that markedly affect DC-mediated TAA retention and cross-priming 87 (panel 12, Figure 2 ) and stimulate antibody-dependent cellular cytotoxicity on established B16 murine melanoma liver micrometastases 88 . Furthermore, Type-I-IFNs were reported to play a major role in the development and differentiation of the Th1 subset, as well as in the generation, activity, expansion and long-term survival of CTLs 89 (panel 13, Figure 2) . Type-I-IFNs are also responsible for the activation of tumoricidal NK cells (panel 14, Figure 2) , which represent one of the host key mechanisms to preempt tumor growth 90 . More recently, the role of Type-I-IFNs in the immunometabolismwhich is an emerging field that investigates the interplay between immunological and metabolic processes 91 -gained increasing appreciation (panel 15, Undoubtedly, understanding the multilevel interactions between metabolic, immunologic and Type-I-IFN nets will offer additional tools to manage beneficial and detrimental Type-I-IFN immune effects and reshape the way Type-I-IFN-IFNAR axis can be exploited therapeutically during infection and cancer.
The role of Type-I-IFNs in anticancer therapy
Although soon after their discovery the antiviral activity of Type-I-IFNs attracted widest interest, the first US Food and Drug Administration (FDA) approval for IFN-α2, in 1986, was for cancer treatment (Figure 3) .
Even before recombinant IFNs were available, reduction of disease morbidities with partially purified IFN-α was reported in several studies performed in patients with hairy-cell leukaemia and chronic myelogenous leukaemia 95, 96 . In both cases, however, over time more effective therapeutic regimens than IFN have been devised (e.g., the targeted inhibitor of the activated BCR-ABL tyrosine kinase Imatinib 97 ). In following clinical studies, the therapeutic effectiveness of IFN-α2, either as unmodified recombinant proteins or pegylated variants, in inducing at least partial disease regression was reported for other hematological and solid tumors including myelomas, lymphomas, melanomas, Kaposi's sarcoma, and renal-cell and bladder carcinoma 98 . To date, IFN-α2 is still commonly employed combined with IL-2 in immunotherapeutic regimens for metastatic renal-cell carcinomas and cutaneous melanoma 99, 100 . In addition, more than 100 clinical trials are currently underway worldwide using IFN-α2 as monotherapy or in combination regimens for both hematological and solid malignancies (for further details please refer to ClinicalTrials.gov and ref.
101).
A wide range of conventional chemotherapy, radiotherapy and immunotherapy, including oncolytic virotherapy, currently licensed for use in humans, are particularly successful if they induce tumor-targeting immune responses 102, 103 . The current view is that therapeutic agents must induce a sort of 'viral mimicry', i.e., a combination of stress signals that are usually linked to viral infection such as Type-I-IFNs and are believed to contribute to their clinical effectiveness. We recently showed that Type-I-IFNs lie at the nexus that controls immunogenic cell death (ICD) and constitutes a hallmark of successful chemotherapy 2 . In particular, we showed that the treatment of various tumor types (e.g., MCA205-fibrosarcomas and AT3breast carcinoma) with anthracyclines or oxaliplatin gave rise to the rapid production of Type-I-IFNs, thus mimicking the immune reactions evoked by viruses. We also elucidated the mechanism of Type-I-IFNmediated ICD demonstrating that (1) hit dying cancer cells emit self nucleic-acids (especially single-stranded RNAs) in the TME, which are sensed by TLR3 on surrounding yet viable cells; and (2) released Type-I-IFNs act as the primum movens for the sequential events bridging innate and cognate antiviral immunity through a specific ISG signature that includes soluble chemotactic mediators such as the C-X-C motif chemokine ligand (CXCL)10. This is crucial for the recruitment, selection and differentiation/maturation of engulfing cells thus dictating the immunogenic outcome of cell death. Corroborating this evidence, the efficacy of anthracyclines was lost upon co-administration of anti-IFNAR or anti-IFN-α/β neutralizing antibodies 2 . Importantly, in breast cancer patients, increased expression levels of the ISG MX dynamin-like GTPase (MX)1 predicted the likelihood of response to anthracycline-based treatment in neoadjuvant and adjuvant settings 2 . In previous studies, Type-I-IFNs were described as crucial mediators of the off-target immunomodulatory effects of cyclophosphamide, an alkylating agent inducing ICD 104 responsible for the expansion of memory CD4 + and CD8 + T cells 105 as well as of DCs 104 . In patients with hematological malignancies, the administration of highdose cyclophosphamide induced a rapid, transient and broad transcriptional modulation on peripheral blood mononuclear cells resulting in DNA damage, cell death and, noticeably, a Type-I-IFN signature 106 . This promoted the establishment of a systemic sterile inflammatory response characterized by the release of endogenous adjuvant signals able to enhance the efficacy of immunotherapy 106 . Similar to chemotherapy, radiation therapy was also reported to increase the levels of Type-I-IFNs and CXCL10 in the TME 107 . In one of these studies, CXCL10 was shown to promote tumor CD8 + T cell-homing and cytolytic activity 107 .
Subsequent observations revealed that radiation-mediated antitumor immunity in immunogenic tumors requires a functional cytosolic DNA-sensing pathway upstream of Type-I-IFNs 108 . Accordingly, Hartlova and colleagues recently found that in the absence of ataxia-telangiectasia mutated (ATM, which is an apical component of the DNA damage response) the accumulation of DNA lesions generated spontaneously or provoked by irradiation induced Type-I-IFNs by STING-mediated signalling 32 . Type-I-IFNs in turn primed the innate immune system for a rapid and amplified response to microbial and environmental threats. In addition, Type-I-IFNs boosted the antineoplastic activity of antibodies specific for oncogenic receptors, such as epidermal growth factor receptor (EGFR) and human EGFR (HER)2, mobilizing DCs to cross-present TAA to CTLs 74 . However, despite these observations strongly support the antitumor and immune-stimulatory effects of Type-I-IFNs, paradoxical proofs of a dichotomous, detrimental tumor growth-promoting role for these cytokines are also reported. In this context, some harmful effects seem to depend on the ability to induce immune-checkpoint pathways as a major mechanism of immune-resistance, particularly against CTLs specific for TAAs. As reported above, Type-I-IFNs upregulate PD-L1 in tumor cells 2, 74 , which can lead to T cell exhaustion 109 . It remains a central goal of studies on tumor immunity to elucidate the multitude of molecular nets activated by Type-I-IFNs. Big issues to solve are when and through which pathways Type-I-IFNs counteract or promote tumor growth. These insights will likely pave the way to more effective IFNbased immunotherapies.
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Conclusions and perspectives
Type-I-IFNs are among the most pleiotropic cytokines and are produced and sensed by almost every cell type in the body. The discovery of Type-I-IFN role in cancer immune-surveillance at first, and cancer immuneediting later, made these cytokines and the immune sensing networks that drive their production very attractive for deeper investigation in preclinical and clinical contexts. As cancer-related genomic information is constantly published, it is emerging that Type-I-IFNs can be produced by, and act on, both malignant and Matter-of-factly, Type-I-IFNs have more than reached the potential envisioned by early discovering virologists, however answering these questions will certainly have a tremendous impact on tumor immunology and biomedicine.
Disclosure of interest
The authors declare no conflicts of interest. (6), tumor-cell stemness (7) , and the upregulation of immuneinhibitory signals such as PD-L1 (8) . Second, acting on the vascular and lymphatic system Type-I-IFNs inhibit angiogenesis through VEGF downregulation (9) . Finally, acting on the immune system Type-I-IFNs stimulate the maturation of DCs (10), promote the release of pro-inflammatory cytokines (11), favor CTL cross-priming (12) , foster the activation and survival of CD8 + and CD4 + T cells (13) and of NK cells (14), have a crucial role on core energetic metabolism regulation (15) , and negatively regulate immune suppressive 35 Treg cells (16) and MDSCs (17) . CSC: cancer stem cell; CTL, cytotoxic T lymphocyte; DC: dendritic cell;
EMT: epithelial-to-mesenchymal transition; IFNs: interferons; MDSCs: myeloid-derived suppressor cells;
MHC-I: major histocompatibility complex-I; NK: natural killer; PD1: programmed death 1; PD-L1:
programmed death-ligand 1; TAAs: tumor-associated antigens; TCA: tricarboxylic acid; Treg: regulatory T cells; VEGF: vascular endothelial growth factor; VLS: vascular and lymphatic system. 
